Matthew Betzenhauser
Research Subjects
Matthew Betzenhauser has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alan C. Rigby
HiberCell Inc., 619 West 54th Street, New York, NY 10019, USA
1 shared publication - An-Hu Li
HiberCell Inc., 619 West 54th Street, New York, NY 10019, USA
1 shared publication - David Surguladze
HiberCell Inc., New York, New York, USA
1 shared publication - Guangyu Zhu
Crystallography Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
1 shared publication - Hongwen Du
Pharmaron Beijing Co., Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
1 shared publication - Jennifer Gasparek
Curia, 1001 Main Street, Buffalo, NY 14203, USA
1 shared publication
Latest Publications
- Open Access
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2233
Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) responsible for regulating protein synthesis and alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway biology in vitro and in vivo, with pharmacokinetics suitable for once-a-day oral dosing in mice.
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2233
Open AccessOptimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) responsible for regulating protein synthesis and alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway biology in vitro and in vivo, with pharmacokinetics suitable for once-a-day oral dosing in mice.